M’Bouye Doucoure

ORCID: 0000-0003-1161-0915
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Malaria Research and Control
  • Mosquito-borne diseases and control
  • SARS-CoV-2 and COVID-19 Research
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 detection and testing
  • Vibrio bacteria research studies
  • COVID-19 epidemiological studies
  • Vaccine Coverage and Hesitancy
  • HIV Research and Treatment
  • Digital Imaging for Blood Diseases
  • Hemoglobinopathies and Related Disorders
  • Travel-related health issues
  • Drug-Induced Hepatotoxicity and Protection

Université des Sciences, des Techniques et des Technologies de Bamako
2017-2024

National Institute of Allergy and Infectious Diseases
2024

National Institutes of Health
2022-2024

Frederick National Laboratory for Cancer Research
2024

University of Bamako
2021-2023

CIS43LS is a monoclonal antibody that was shown to protect against controlled Plasmodium falciparum infection in phase 1 clinical trial. Whether can prevent P. region which the endemic unknown.We conducted 2 trial assess safety and efficacy of single intravenous infusion healthy adults Mali over 6-month malaria season. In Part A, assessed at three escalating dose levels. B, participants were randomly assigned (in 1:1:1 ratio) receive 10 mg per kilogram body weight, 40 kilogram, or placebo....

10.1056/nejmoa2206966 article EN New England Journal of Medicine 2022-11-01

BackgroundSubcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether administered subcutaneously can protect children from P. region where this organism is endemic unclear.MethodsWe conducted 2 trial Mali to assess safety and efficacy subcutaneous 6 10 years age over 6-month malaria season. In part A trial, was assessed at three dose levels adults, followed by assessment two children. B were...

10.1056/nejmoa2312775 article EN New England Journal of Medicine 2024-04-29

The extent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure and transmission in Mali the surrounding region is not well understood. We aimed to estimate cumulative incidence SARS-CoV-2 3 communities understand factors associated with infection.

10.1093/cid/ciab589 article EN public-domain Clinical Infectious Diseases 2021-06-29

ABSTRACT Background The extent of SARS-CoV-2 exposure and transmission in Mali the surrounding region is not well understood, although infection has been confirmed nearly 14,000 symptomatic individuals their contacts since first case March 2020. We aimed to estimate cumulative incidence three Malian communities, understand factors associated with infection. Methods Between 27 July 2020 29 January 2021, we collected blood samples along demographic, social, medical self-reported symptoms...

10.1101/2021.04.26.21256016 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2021-04-29

ABSTRACT Serological tests are an indispensable tool to understand the epidemiology of SARS-CoV-2 pandemic, particularly in areas where molecular diagnostics limited. Poor assay performance may hinder utility these tests, including high rates false-positivity previously reported sub-Saharan Africa. From 312 Malian samples collected prior 2020, we measured antibodies commonly tested antigens and four other betacoronaviruses by ELISA, assessed functional cross-reactivity a subset pseudovirus...

10.1101/2021.03.08.21252784 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2021-03-12

Background: Plasmodium falciparum (Pf) parasitemia during pregnancy causes maternal, fetal, and infant mortality. We conducted two trials in Ouélessébougou, Mali to optimize PfSPZ Vaccine dosage, schedule, antimalarial pre-treatment for future maternal immunizations.Methods: In MLSPZV3 trial (NCT03510481), we randomly assigned healthy 18-35-year-olds 3 doses of 9x105 (versus placebo) at 0,1,4-weeks or 0,8,16-weeks without pre-treatment, with 1-year booster dose. MLSPZV4 (NCT03989102),...

10.2139/ssrn.4769103 preprint EN 2024-01-01

Background: Serological tests are an indispensable tool to understand the epidemiology of SARS-CoV-2 pandemic, particularly in areas where molecular diagnostics limited. Poor assay performance may hinder utility these tests, including high rates false-positivity previously reported sub-Saharan Africa.Methods: From 312 Malian samples collected prior 2020, we measured antibodies commonly tested antigens and four other betacoronaviruses by ELISA, assessed functional cross-reactivity a subset...

10.2139/ssrn.3802506 article EN SSRN Electronic Journal 2021-01-01

The epidemiological characterization of transmission reservoirs is a critical step in preparation for interventional trials malaria elimination/eradication. Using cluster sampling and households/compounds as units sampling, we recruited followed monthly, from June 2011 to 2012, 250 volunteers 3 months 50 years age Bancoumana, Mali. In July only participants 5-35 (N = 121) were reenrolled an additional year. Malaria infection prevalence was highest October both (21.5%, 50/233) 2012 (38.2%,...

10.4269/ajtmh.15-0845 article EN American Journal of Tropical Medicine and Hygiene 2017-05-23

ABSTRACT. The interpretation of a laboratory test result requires an appropriate reference range established in healthy subjects, and normal ranges may vary by factors such as geographic region, sex, age. We examined hematological clinical chemistry parameters residents at two rural vaccine trial sites: Bancoumana Doneguebougou Mali, West Africa. During screening studies 2018 2019, peripheral blood samples from 1,192 apparently individuals age 6 months to 82 years were analyzed accredited...

10.4269/ajtmh.23-0719 article EN American Journal of Tropical Medicine and Hygiene 2024-03-26

<h3>Background</h3> Serosurveillance is an important method to help monitor COVID-19 in the community Mali. We previously adapted and qualified a two-antigen Enzyme-Linked Immunosorbent Assays for use local laboratories using venous blood samples (95% CI, 73.9% (51.6–89.8) 99.4% (97.7–99.9)) respectively as sensitivity specificity). However, burden of collection set cost can be challenging resource limited region where alternative source biological material will facilitate large scale...

10.1136/bmjgh-2023-edc.261 article EN 2023-12-01
Coming Soon ...